Mineralys Therapeutics (MLYS) Soars 88.7% on ASI Breakthrough Momentum

Summary
• Mineralys Therapeutics (MLYS) surges 88.7% to $29.21, hitting 52-week high of $30.14
• Turnover spikes to 14.65 million shares, 34.2% of float
• AstraZeneca’s Baxdrostat trial success sparks ASI sector domino effect

Mineralys Therapeutics (MLYS) has ignited a historic intraday rally, surging 88.7% to $29.21 as positive phase III data from AstraZeneca’s Baxdrostat trial catalyzed momentum across the aldosterone synthase inhibitor (ASI) space. The stock’s meteoric rise—up from $22.00 to $30.14—reflects a sector-wide re-rating of ASI candidates, with MLYS’s own Lorundrostat trials adding tailwinds. This surge underscores the sector’s sensitivity to clinical milestones and regulatory tailwinds.

Aldosterone Synthase Inhibitor Sector Rally Ignites MLYS Surge
Mineralys’s explosive move stems from AstraZeneca’s (AZN) positive phase III results for Baxdrostat, a direct competitor in the ASI class. The 9.8mmHg placebo-adjusted systolic blood pressure reduction in Baxdrostat’s trial validated the therapeutic potential of ASIs, triggering a domino effect across the sector. Mineralys’s own phase II/III data—showing 11.7mmHg and 7.9mmHg reductions in systolic blood pressure—positioned Lorundrostat as a viable alternative, amplifying investor enthusiasm. The stock’s 88.7% gain reflects both direct trial validation and broader sector re-rating.

Biotech Sector Volatility Amplified by ASI Class Momentum
The biotech sector (IBB) saw mixed performance, with ASI-focused peers like Cytokinetics (CYTK, +41.1%) and Ionis Pharmaceuticals (IONS, +35.6%) outperforming. AstraZeneca’s AZN +0.1% provided indirect validation, while broader biotech indices lagged. MLYS’s 88.7% gain far exceeded sector averages, highlighting the ASI class’s unique catalyst-driven momentum. This divergence underscores the sector’s reliance on clinical-stage breakthroughs rather than macroeconomic trends.

Options Playbook: Leveraging MLYS Volatility with Strategic Calls
• 200-day MA: $13.19 (well below current price)
• RSI: 68.9 (overbought but not extreme)
• MACD: 0.359 (bullish crossover with signal line 0.224)
• Bollinger Bands: $12.42–$16.11 (price far above range)

Mineralys’s technicals scream short-term continuation. Key resistance lies at $30.14 (52-week high), with support at $22.00 (intraday low). The 68.9 RSI suggests overbought conditions but not extreme, while the MACD histogram (0.136) confirms bullish momentum. Aggressive bulls should target $30.14–$32.00, with a stop below $22.00. No leveraged ETF data is available, but the stock’s standalone volatility justifies options-heavy strategies.

Top Option 1: MLYS20250919C30
• Code: MLYS20250919C30
• Type: Call
• Strike: $30.00
• Expiration: 2025-09-19
• IV: 104.66% (high volatility)
• Leverage: 12.18% (moderate)
• Delta: 0.5056 (mid-range sensitivity)
• Theta: -0.1044 (rapid time decay)
• Gamma: 0.0587 (moderate price sensitivity)
• Turnover: $228,120 (liquid)

This call offers 266.67% price change potential with a 12.18% leverage ratio. The high IV (104.66%) reflects market anticipation of continued ASI sector momentum. Theta (-0.1044) and gamma (0.0587) suggest rapid decay but strong responsiveness to price swings. A 5% upside to $30.67 would yield a 22.2% payoff (max(0, 30.67-30)).

Top Option 2: MLYS20251017C30
• Code: MLYS20251017C30
• Type: Call
• Strike: $30.00
• Expiration: 2025-10-17
• IV: 79.00% (moderate)
• Leverage: 9.74% (lower)
• Delta: 0.5268 (mid-range)
• Theta: -0.0469 (slower decay)
• Gamma: 0.0485 (moderate)
• Turnover: $3,087 (less liquid)

This call balances IV (79.00%) with a 9.74% leverage ratio. The 0.5268 delta ensures moderate sensitivity to price moves, while theta (-0.0469) and gamma (0.0485) suggest slower decay but steady responsiveness. A 5% upside to $30.67 would yield a 22.2% payoff (max(0, 30.67-30)).

Aggressive Play: Buy MLYS20250919C30 for a 266.67% price change potential. Conservative Play: Buy MLYS20251017C30 for a 8.30% price change with lower decay. If $30.14 breaks, consider rolling into MLYS20251219C30 (leverage 6.80%) for longer-term exposure.

Backtest Mineralys Stock Performance

Act Now: MLYS at Inflection Point as ASI Sector Gains Traction
Mineralys’s 88.7% surge is a textbook example of sector-driven momentum, fueled by AstraZeneca’s Baxdrostat validation and its own robust phase II/III data. The stock’s 52-week high at $30.14 and 68.9 RSI suggest overbought conditions, but the MACD histogram (0.136) and bullish gamma (0.0587) in top options indicate strong continuation potential. Investors should monitor $30.14 as a critical resistance level—breakout confirms a new bull phase, while a breakdown triggers a retest of $22.00. Meanwhile, sector leader AstraZeneca (AZN) rose 0.1%, signaling broader ASI class validation. Act now: Buy MLYS20250919C30 for a 266.67% price change potential if $30.14 holds.